Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lactic dehydrogenase estimation in haematological malignancies.

N G Flanagan1, J C Ridway, C C Platt

  • 1Department of Haematology, Victoria Hospital, Blackpool, UK.

Clinical and Laboratory Haematology
|January 1, 1989
PubMed
Summary

Serum lactic dehydrogenase (LDH) is a valuable biomarker for diagnosing and monitoring hematological malignancies. Rising LDH levels can indicate disease progression or relapse, even if initial levels were normal.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Duplication of chromosome 2 in association with ventriculomegaly - a case report.

Prenatal diagnosis·2002
Same author

Resolving factor analysis.

Analytical chemistry·2001
Same author

Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution.

Clinical and laboratory haematology·2000
Same author

Play and culture.

Paediatric nursing·2000
Same author

Antimony and sudden infant death syndrome.

Lancet (London, England)·1998
Same author

Prenatal diagnosis of extra-amniotic pregnancy.

British journal of obstetrics and gynaecology·1995

Area of Science:

  • Clinical Chemistry
  • Hematology
  • Oncology

Background:

  • Serum lactic dehydrogenase (LDH) has been implicated in hematological and other malignancies.
  • LDH testing is not yet a routine diagnostic or monitoring tool in many clinical settings.

Purpose of the Study:

  • To re-evaluate the clinical utility of serum LDH levels in patients with hematological malignancies.
  • To assess the diagnostic and prognostic value of LDH in this patient cohort.

Main Methods:

  • Retrospective analysis of serum LDH levels in 278 patients with hematological malignancies.
  • Comparison of LDH levels at diagnosis and during follow-up.
  • Analysis of routine biochemical screen data for LDH prevalence.

Main Results:

Related Experiment Videos

  • Abnormal serum LDH levels were detected at diagnosis in 42% of patients with hematological malignancies.
  • Only 4% of over 23,000 routine biochemical screens showed abnormal LDH levels.
  • Increasing LDH levels during follow-up frequently indicated progressive or relapsing disease, including in patients with initially normal LDH.

Conclusions:

  • Serum LDH is a significant indicator in hematological malignancies, with higher diagnostic prevalence than routine screening suggests.
  • LDH monitoring is crucial for detecting disease progression or relapse in hematological cancer patients.
  • The study supports the broader implementation of serum LDH testing in managing hematological malignancies.